Exelixis, Inc. (EXEL)

Market Cap	11.47B +21.3%
Revenue (ttm)	2.32B +7.0%
Net Income	782.57M +50.1%
EPS	2.78 +58.0%
Shares Out	259.71M
PE Ratio	15.88
Forward PE	14.43
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,736,257
Open	44.15
Previous Close	44.47
Day's Range	43.75 - 44.65
52-Week Range	32.38 - 49.62
Beta	0.42
Analysts	Buy
Price Target	46.60 (+5.53%)
Earnings Date	Feb 10, 2026

About EXEL

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 7, 2000
• Employees: 1,077
• Stock Exchange: NASDAQ
• Ticker Symbol: EXEL
• Website: https://www.exelixis.com

Financial Performance

In 2025, Exelixis's revenue was $2.32 billion, an increase of 6.98% compared to the previous year's $2.17 billion. Earnings were $782.57 million, an increase of 50.13%.

Analyst Summary

According to 21 analysts, the average rating for EXEL stock is "Buy." The 12-month stock price target is $46.6, which is an increase of 5.53% from the latest price.

Price Target

$46.6

(5.53% upside)

Analyst Consensus: Buy